No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT

作者：Sinead Delany‐Moretlwe, Hakim‐Moulay Dehbi, Izukanji Sikazwe, George B. Kyei, Kwadwo Koram, Erik R. Dubberke, Noluthando Mwelase, Dominic Hague, Linda‐Gail Bekker, Linda Yun, Annaléne Nel, Leon du Toit, Bruce Biccard, Katherine Gill, Chikumbutso Chipeta, Kathryn Mngadi, Limakatso Lebina, Reshmi Dassaye, Villeshni Asari, Samantha H. Fry, Edwin Turton, Khatija Ahmed, Kwadwo Asamoah Kusi, Susan Adu-Amankwah, Roma Chilengi, Joyce Chilekwa, Laurence Lovat, Dermot McGuckin, Emilia Caverly, Mary C. Politi, Ben Swan, Anne K. DeSchryver, Sherry McKinnon, Ananya Gupta, Gemma Jones, Nicholas Freemantle, Shabaana A. Khader, Helen Rees, Mihai G. Netea, Ramani Moonesinghe, Michael S. Avidan · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1588190 · 被引用次数：1 · 研究领域：Immune responses and vaccinations、SARS-CoV-2 and COVID-19 Research、Vaccine Coverage and Hesitancy

Background: Measles-containing vaccines (MCV), by training innate immune cells, are hypothesized to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19). Methods: In this international, double-blind, placebo-controlled trial, we randomly assigned adults, 18 years and older, to receive MCV or saline. The primary outcome was polymerase chain reaction (PCR) confirmed symptomatic COVID-19, up to 60 days after intervention. Secondary outcomes were PCR-confirmed symptomatic COVID-19 and serologically confirmed SARS-CoV-2 infection, up to 150 days after intervention. Results: Of 3411 randomised participants, the modified intention-to-treat population included 1607 in the MCV and 1545 in the saline group. The estimated risk of symptomatic COVID-19 by 60 days was 1.5% in the MCV and 1.2% in the saline group (risk difference, 0.3 percentage points, 95% CI, -0.5 to 1.1; p=0.52). At 150 days, these percentages were 4.1% (65/1585) and 4.1% (64/1544) in the MCV and saline groups, respectively (risk difference, 0.04 percentage points, 95% CI, -1.4 to 1.3; p=0.95). Based on serology results available at 0 and 150 days, 10.6% (100/945) of participants in the MCV and 10.3% (98/951) in the saline group had infection with SARS-CoV-2 over the course of the trial (risk difference, 0.3 percentage points, 95% CI, -2.6 to 3.1; p=0.84). Three patients were hospitalised with COVID-19 disease in the MCV and one in the saline group. Conclu...